$MIRM september accumulation 👁🗨
Diupdate
*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharmaceuticals announced a shelf offering of $10 million today. This created an excellent buying opportunity which we used as our first entry. My team will be using the rest of September to build our position. We are expecting a bullish run before the end of the year, but if one happens sooner, we will of course act in our favor and do what we think is best.
Entry: $22.80
Take Profit: Somewhere above $32
If you want to see more, please like and follow us SimplyShowMeTheMoney
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharmaceuticals announced a shelf offering of $10 million today. This created an excellent buying opportunity which we used as our first entry. My team will be using the rest of September to build our position. We are expecting a bullish run before the end of the year, but if one happens sooner, we will of course act in our favor and do what we think is best.
Entry: $22.80
Take Profit: Somewhere above $32
If you want to see more, please like and follow us SimplyShowMeTheMoney
Catatan
2nd Entry: $22.30Catatan
3rd entry at $18.75!Catatan
Holding. We're prepared for a retrace back to $18.75Trading ditutup: target tercapai
We are currently up 8% on 
MIRM and holding 3 positions. We are exiting today because we believe that the stock market will head lower soon. We will be back!
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.